BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022
October 12 2022 - 1:00PM
Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI),
announced today that they will be participating in Renmark
Financial Communications Inc.’s live Virtual Non-Deal Roadshow
Series to discuss its latest investor presentation on Friday,
October 14, at 10:00 AM EDT, and Tuesday October 18, at 1:00PM CDT.
Biofrontera Inc. welcomes stakeholders, investors, and other
individual followers to register and attend this live event.
“These virtual presentations are the first in a
series focused on investors in different parts of the United
States. In the coming weeks, we plan similar presentations on a
regular basis, aiming to inform a broad investor base about
Biofrontera's business strategy and recent corporate developments”,
said Erica Monaco, CEO of Biofrontera Inc.
The presentations will feature Prof. Hermann
Luebbert, Executive Chairman and Erica Monaco, CEO. Topics to be
covered will include the latest investor presentation followed by a
live Q&A. Investors interested in participating in one of these
events will need to register using the links below. As a reminder,
registration for the live event may be limited, but access to the
replay after the event will be on the company’s investor page.
REGISTER HERE:
Friday, October 14,
2022:https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-bfri-2022-10-14-100000
Tuesday, October 18,
2022:https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-bfri-2022-10-18-130000
- To ensure smooth
connectivity, please access this link using the latest version of
Google Chrome.
About Biofrontera
Inc.Biofrontera is a U.S.-based biopharmaceutical company
commercializing a portfolio of pharmaceutical products focused on
the fields of photodynamic therapy and topical antibiotics. In
collaboration with healthcare providers, we are fully committed to
advancing treatment options and patient care. Biofrontera, Inc. was
founded in March 2015 to commercialize the FDA-approved flagship
drug Ameluz® (aminolevulinic acid hydrochloride) gel, 10%, in the
United States. In 2019, Biofrontera Inc. expanded its U.S.-product
portfolio with the FDA-approved drug Xepi® (ozenoxacin) cream, 1%.
With both FDA-approved products, Biofrontera Inc. is ideally
positioned for sustainable growth.
About Renmark Financial Communications
Inc.Founded in 1999, Renmark Financial Communications Inc.
is North America’s leading retail investor relations firm.
Employing a strategic and comprehensive mix of exposure tactics;
Renmark hosts Virtual Non-Deal Roadshows as well as in-person
corporate presentations and maintains daily communications with
thousands of brokers and money managers across Canada and the
United States. Renmark empowers its publicly traded clientele to
maximize their visibility within the financial community and
strengthen their investor audience.
CONTACT:Renmark Financial Communications
Inc.Robert Thaemlitz: rthaemlitz@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680www.renmarkfinancial.com
Biofrontera Inc.us-ir@biofrontera.com
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Oct 2023 to Oct 2024